DK1328269T5 - Kombination af en CB1-receptorantagonist og sibutramin til behandling af fedme - Google Patents

Kombination af en CB1-receptorantagonist og sibutramin til behandling af fedme

Info

Publication number
DK1328269T5
DK1328269T5 DK01974413T DK01974413T DK1328269T5 DK 1328269 T5 DK1328269 T5 DK 1328269T5 DK 01974413 T DK01974413 T DK 01974413T DK 01974413 T DK01974413 T DK 01974413T DK 1328269 T5 DK1328269 T5 DK 1328269T5
Authority
DK
Denmark
Prior art keywords
receptor antagonist
obesity
sibutramine
treatment
combination
Prior art date
Application number
DK01974413T
Other languages
English (en)
Other versions
DK1328269T3 (da
DK1328269T4 (da
Inventor
Odile Piot-Grosjean
Philippe Picaut
Francois Petitet
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8854974&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1328269(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of DK1328269T3 publication Critical patent/DK1328269T3/da
Application granted granted Critical
Publication of DK1328269T4 publication Critical patent/DK1328269T4/da
Publication of DK1328269T5 publication Critical patent/DK1328269T5/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK01974413T 2000-10-04 2001-10-01 Kombination af en CB1-receptorantagonist og sibutramin til behandling af fedme DK1328269T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0012646A FR2814678B1 (fr) 2000-10-04 2000-10-04 Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
PCT/FR2001/003022 WO2002028346A2 (fr) 2000-10-04 2001-10-01 Association d'un antagoniste du recepteur cb1 et de sibutramine, pour le traitement de l'obesite

Publications (3)

Publication Number Publication Date
DK1328269T3 DK1328269T3 (da) 2004-09-20
DK1328269T4 DK1328269T4 (da) 2008-11-24
DK1328269T5 true DK1328269T5 (da) 2009-03-16

Family

ID=8854974

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01974413T DK1328269T5 (da) 2000-10-04 2001-10-01 Kombination af en CB1-receptorantagonist og sibutramin til behandling af fedme

Country Status (29)

Country Link
EP (1) EP1328269B2 (da)
JP (1) JP4221221B2 (da)
KR (1) KR20030036885A (da)
CN (1) CN100409845C (da)
AT (1) ATE267595T1 (da)
AU (2) AU2001293936B2 (da)
BG (1) BG107739A (da)
BR (1) BR0114410A (da)
CA (1) CA2424934A1 (da)
DE (1) DE60103556T3 (da)
DK (1) DK1328269T5 (da)
EA (1) EA005924B1 (da)
EE (1) EE200300121A (da)
ES (1) ES2217191T5 (da)
FR (1) FR2814678B1 (da)
HR (1) HRP20030249A2 (da)
HU (1) HUP0302044A3 (da)
IL (1) IL155236A0 (da)
MX (1) MXPA03002845A (da)
NO (1) NO20031521L (da)
NZ (1) NZ524904A (da)
PL (1) PL362833A1 (da)
PT (1) PT1328269E (da)
SI (1) SI1328269T2 (da)
SK (1) SK4032003A3 (da)
TR (1) TR200401264T4 (da)
WO (1) WO2002028346A2 (da)
YU (1) YU26103A (da)
ZA (1) ZA200303015B (da)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2833842B1 (fr) * 2001-12-21 2004-02-13 Aventis Pharma Sa Compositions pharmaceutiques a base de derives d'azetidine
ATE486842T1 (de) 2002-03-12 2010-11-15 Merck Sharp & Dohme Substituierte amide
US7423067B2 (en) 2002-03-26 2008-09-09 Merck & Co., Inc. Diphenyl cyclopentyl amides as cannabinoid-1 receptor inverse agonists
EP1492784A4 (en) 2002-03-28 2006-03-29 Merck & Co Inc SUBSTITUTED 2,3-DIPHENYLPYRIDINES
CA2481313A1 (en) 2002-04-12 2003-10-23 Merck & Co., Inc. Bicyclic amides
ES2301833T3 (es) 2002-07-29 2008-07-01 Hoffmann La Roche Derivados de benzodioxol.
EP1583742B1 (en) 2003-01-02 2009-12-02 F. Hoffmann-La Roche Ag Cb 1 receptour inverse agonists
KR100674769B1 (ko) 2003-01-02 2007-02-28 에프. 호프만-라 로슈 아게 신규 씨비 1 수용체 역작용제
US7329658B2 (en) * 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
BRPI0411131A (pt) 2003-06-11 2006-07-18 Merck & Co Inc composto, método de tratar uma doença mediada pelo receptor de canabinóide 1, método de previnir a obesidade de uma pessoa com risco de obesidade, composição, e, uso de um composto
KR100809201B1 (ko) 2003-06-20 2008-02-29 에프. 호프만-라 로슈 아게 카나바노이드 수용체 1 역작용제로서 2-아미노벤조티아졸
EP1498122A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Semi-solid systems containing azetidine derivatives
EP1498123A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Emulsifying systems containing azetidine derivatives
CA2537535A1 (en) * 2003-09-02 2005-03-10 Solvay Pharmaceuticals Gmbh Novel medical use of selective cb1-receptor antagonists
FR2861303A1 (fr) * 2003-10-24 2005-04-29 Sanofi Synthelabo Utilisation d'un derive de pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique
WO2005049615A1 (en) * 2003-11-21 2005-06-02 Pfizer Products Inc. Pyrazolo`1,5-a!`1,3,5! triazin -4-one derivatives as cb1 receptor antagonists
ES2298840T3 (es) 2003-12-08 2008-05-16 F. Hoffmann-La Roche Ag Derivados de tiazol.
MXPA06008391A (es) 2004-01-28 2006-08-25 Hoffmann La Roche Nuevos compuestos espiro-pentaciclicos.
CN1950361A (zh) 2004-05-10 2007-04-18 霍夫曼-拉罗奇有限公司 用于治疗肥胖的吡咯或咪唑酰胺化合物
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
CA2581596A1 (en) * 2004-09-29 2006-04-13 Schering Corporation Combinations of substituted azetidonones and cb1 antagonists
FR2876689B1 (fr) * 2004-10-14 2008-02-22 Aventis Pharma Sa Nouveau procede et intermediaires de preparation de derives de n-(1-benzhydryl-azetidin-3-yl)-n-phenyl-methylsulfonamide
JP2008517976A (ja) 2004-10-25 2008-05-29 ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ１カンナビノイド受容体拮抗薬及びカリウムチャンネルオープナーから成る、真性糖尿病１型、肥満及び関連症状の治療用の医薬組成物
BRPI0517369A (pt) 2004-10-27 2008-10-07 Hoffmann La Roche compostos, processo para a sua manufatura, composições que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação de receptores de cb1 e sua utilização
EP1812418B1 (en) 2004-11-09 2010-10-27 F. Hoffmann-La Roche AG Dibenzosuberone derivatives
MX2007012213A (es) 2005-04-06 2007-12-10 Hoffmann La Roche Derivados de piridin-3-carboxamida como agonistas inversos de canabinoides.
US7906652B2 (en) 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
US20080027087A1 (en) * 2006-02-21 2008-01-31 Ampla Pharmaceuticals, Inc. CB1 antagonists and inverse agonists
US8247442B2 (en) 2006-03-29 2012-08-21 Purdue Pharma L.P. Benzenesulfonamide compounds and their use
US8791264B2 (en) 2006-04-13 2014-07-29 Purdue Pharma L.P. Benzenesulfonamide compounds and their use as blockers of calcium channels
TW200812963A (en) 2006-04-13 2008-03-16 Euro Celtique Sa Benzenesulfonamide compounds and the use thereof
US7629346B2 (en) 2006-06-19 2009-12-08 Hoffmann-La Roche Inc. Pyrazinecarboxamide derivatives as CB1 antagonists
WO2008038143A2 (en) * 2006-06-22 2008-04-03 Medichem, S.A. Novel solid forms of rimonabant and synthetic processes for their preparation
EP2057144A4 (en) * 2006-09-01 2010-06-02 Hetero Drugs Ltd NEW POLYMORPHIC FROM RIMONABANT
US7781593B2 (en) 2006-09-14 2010-08-24 Hoffmann-La Roche Inc. 5-phenyl-nicotinamide derivatives
JP5030114B2 (ja) * 2006-09-25 2012-09-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体をモジュレートする化合物
DE102007002260A1 (de) 2007-01-16 2008-07-31 Sanofi-Aventis Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms
EP1953144A1 (en) * 2007-01-30 2008-08-06 Sandoz AG Novel polymorphic forms of N-piperidino-5-(4-chlorophenyl)-1-(2, 4-dichlorphenyl)-4-methyl-3-pyrazolecarboxamide
US8399486B2 (en) 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
WO2009040659A2 (en) 2007-09-28 2009-04-02 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
AR069700A1 (es) * 2007-12-18 2010-02-10 Sanofi Aventis Derivados de azetidina,composiciones farmaceuticas que los comprenden, metodo de preparacion, intermediarios de sintesis,y usos de los mismos en el tratamiento o prevencion de trastornos psiquiatricos , del sistema inmune y gastrointestinales, entre otros.
WO2010079241A1 (es) 2009-01-12 2010-07-15 Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
BRPI0902481B8 (pt) 2009-07-31 2021-05-25 Soc Beneficente De Senhoras Hospital Sirio Libanes composição farmacêutica compreendendo hemopressina e seu uso.
US8410107B2 (en) 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US8669254B2 (en) 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE61928B1 (en) † 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
JPH04360167A (ja) * 1991-06-06 1992-12-14 Mitsubishi Kasei Corp 近接帯電装置
FR2713225B1 (fr) † 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
JPH07209959A (ja) * 1994-01-24 1995-08-11 Ricoh Co Ltd 帯電装置
US5596106A (en) † 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
FR2735774B1 (fr) * 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
US6482927B1 (en) * 1995-11-27 2002-11-19 Millennium Pharmaceuticals, Inc. Chimeric proteins comprising the extracellular domain of murine Ob receptor
GB9619961D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
CA2269660A1 (en) † 1996-10-31 1998-05-07 Merck & Co., Inc. Combination therapy for the treatment of diabetes and obesity
FR2758723B1 (fr) † 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
GB2343550A (en) * 1997-07-29 2000-05-10 Silicon Genesis Corp Cluster tool method and apparatus using plasma immersion ion implantation
EP0920864A1 (en) † 1997-12-03 1999-06-09 Pfizer Products Inc. Combination therapy including a specific beta-3 agonist and an anorectic agent
IL141769A0 (en) † 1998-09-11 2002-03-10 Aventis Pharma Sa Azetidine derivatives, preparation and medicines containing them
FR2783246B1 (fr) * 1998-09-11 2000-11-17 Aventis Pharma Sa Derives d'azetidine, leur preparation et les medicaments les contenant
FR2805817B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
FR2805810B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation

Also Published As

Publication number Publication date
ES2217191T5 (es) 2009-02-16
ZA200303015B (en) 2004-02-26
HUP0302044A2 (hu) 2003-11-28
EP1328269B1 (fr) 2004-05-26
KR20030036885A (ko) 2003-05-09
CN100409845C (zh) 2008-08-13
NZ524904A (en) 2004-11-26
JP4221221B2 (ja) 2009-02-12
TR200401264T4 (tr) 2004-07-21
CN1473040A (zh) 2004-02-04
FR2814678B1 (fr) 2002-12-20
PT1328269E (pt) 2004-08-31
SI1328269T2 (sl) 2008-12-31
SK4032003A3 (en) 2003-09-11
DK1328269T3 (da) 2004-09-20
DE60103556D1 (de) 2004-07-01
BR0114410A (pt) 2004-02-17
ES2217191T3 (es) 2004-11-01
DE60103556T2 (de) 2005-06-30
EE200300121A (et) 2005-04-15
YU26103A (sh) 2006-08-17
WO2002028346A3 (fr) 2002-08-29
EA200300441A1 (ru) 2003-08-28
NO20031521D0 (no) 2003-04-03
SI1328269T1 (en) 2004-10-31
FR2814678A1 (fr) 2002-04-05
IL155236A0 (en) 2003-11-23
ATE267595T1 (de) 2004-06-15
NO20031521L (no) 2003-04-24
EP1328269A2 (fr) 2003-07-23
BG107739A (bg) 2004-01-30
DE60103556T3 (de) 2009-04-09
HRP20030249A2 (en) 2005-02-28
AU9393601A (en) 2002-04-15
WO2002028346A2 (fr) 2002-04-11
PL362833A1 (en) 2004-11-02
HUP0302044A3 (en) 2005-05-30
EA005924B1 (ru) 2005-08-25
JP2004512279A (ja) 2004-04-22
DK1328269T4 (da) 2008-11-24
EP1328269B2 (fr) 2008-07-30
AU2001293936B2 (en) 2007-01-25
MXPA03002845A (es) 2004-09-10
CA2424934A1 (fr) 2002-04-11

Similar Documents

Publication Publication Date Title
DK1328269T3 (da) Kombination af en CB1-receptorantagonist og sibutramin til behandling af fedme
TR200202194T2 (tr) Poliglütamik asit-kamptotesin birleşikleri ve hazırlama yöntemleri
HK1061649A1 (en) N-(2-arylethyl) benzylamines as antagonists of the5-ht6 receptor
DK1301436T3 (da) Fremgangsmåder til syntese af et oxidationsmiddel samt dets anvendelse
CY1106366T1 (el) Ενωση λακταμης για την αναστολη της απελευθερωσης ή της συνθεσης βητα-αμυλοειδους πεπτιδιου
IS6806A (is) Samsetningar af lyfjum (t.d. klórprómasíni og pentamídíni) fyrir meðhöndlun á æxlistruflunum
AU3652102A (en) Compounds and their uses
MXPA03007140A (es) Derivados de carbolina.
WO2002064125A3 (en) Use of a farnesoid x receptor antagonist for treating hyperlipidemia
DK1383742T3 (da) Syntese og fremgangsmåder til anvendelse af tetrahydroindolonanaloge og derivater
IT1317747B1 (it) Apparecchiatura ancillare per protesi di ginocchio.
DK1441761T3 (da) Fremgangsmåder til forebyggelse og behandling af flavivirus-infektion hos dyr
SE0302361D0 (sv) Inhibering av upptagning av monoamin
DK1177191T3 (da) Substituerede benzimidazoler, fremstilling og anvendelse deraf som midler til bekæmpelse af parasitiske protozoer
DK1420789T3 (da) Anvendelse af aktivstoffer med my-opioid-receptoragonistisk virkning og opioid-receptorantagonistisk virkning som kombinationslægemidler til cancerbehandling
MXPA03006970A (es) Nuevo uso de iloperidona.
ATE328595T1 (de) Carvedilolpolymorph
DK1366033T3 (da) Kemiske forbindelser
DK1377294T3 (da) Anvendelse af neuroaktive stoffer til behandling af Parkinson's sygdom og farmaceutisk kombination
IT1317742B1 (it) Composizioni a rilascio controllato di metamizolo e tramadolo.